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Abstract
Background: Spinal cord injury (SCI) presents a significant challenge for the field of neurotherapeutics. Stem cells
have shown promise in replenishing the cells lost to the injury process, but the release of axon growth-inhibitory
molecules such as chondroitin sulfate proteoglycans (CSPGs) by activated cells within the injury site hinders the
integration of transplanted cells. We hypothesised that simultaneous application of enteric neural stem cells (ENSCs)
isolated from the gastrointestinal tract, with a lentivirus (LV) containing the enzyme chondroitinase ABC (ChABC),
would enhance the regenerative potential of ENSCs after transplantation into the injured spinal cord.
Methods: ENSCs were harvested from the GI tract of p7 rats, expanded in vitro and characterised. Adult rats
bearing a contusion injury were randomly assigned to one of four groups: no treatment, LV-ChABC injection only,
ENSC transplantation only or ENSC transplantation+LV-ChABC injection. After 16 weeks, rats were sacrificed and the
harvested spinal cords examined for evidence of repair.
Results: ENSC cultures contained a variety of neuronal subtypes suitable for replenishing cells lost through SCI.
Following injury, transplanted ENSC-derived cells survived and ChABC successfully degraded CSPGs. We observed
significant reductions in the injured tissue and cavity area, with the greatest improvements seen in the combined
treatment group. ENSC-derived cells extended projections across the injury site into both the rostral and caudal
host spinal cord, and ENSC transplantation significantly increased the number of cells extending axons across the
injury site. Furthermore, the combined treatment resulted in a modest, but significant functional improvement by
week 16, and we found no evidence of the spread of transplanted cells to ectopic locations or formation of
tumours.
Conclusions: Regenerative effects of a combined treatment with ENSCs and ChABC surpassed either treatment
alone, highlighting the importance of further research into combinatorial therapies for SCI. Our work provides
evidence that stem cells taken from the adult gastrointestinal tract, an easily accessible source for autologous
transplantation, could be strongly considered for the repair of central nervous system disorders.
Keywords: Spinal cord injury, Stem cells, Enteric neural stem cells, ChABC
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: alan.burns@ucl.ac.uk
1Stem Cells and Regenerative Medicine, UCL Great Ormond Street Institute
of Child Health, London, UK
6Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The
Netherlands
Full list of author information is available at the end of the article
Jevans et al. Stem Cell Research & Therapy           (2021) 12:10 
https://doi.org/10.1186/s13287-020-02031-9
Background
Spinal cord injury (SCI) is a devastating condition with
an estimated UK prevalence of approximately 40,000 [1].
The injury process occurs biphasically, beginning with
axonal damage and cell death as a direct result of the
initiating trauma [2], and proceeding with haemorrhage
[3], immune infiltration [4], extensive cell death/axonal
degeneration and astroglial activation [5]. Activated as-
trocytes and other reactive cells secrete chondroitin-
sulfate proteoglycans (CSPGs) [6–11], which induce
axon growth cone collapse and prevent axons from
sprouting across the injury site [12, 13]. Currently, there
is no effective cure for SCI.
Cell-based therapies for SCI hold great promise in
terms of cell replacement [14, 15], modification of the
inhibitory micro-environment [16] and endogenous neu-
roprotection [17]. Stem cells from various sources have
been examined. Mesenchymal stem cells have been
shown to nullify the inhibitory micro-environment that
develops following SCI, resulting in increased endogen-
ous regeneration [18]. Transplantations of olfactory en-
sheathing glia (OEG) isolated from the olfactory bulb
have resulted in considerable motor and sensory im-
provements after injury [19]. Neural stem cells taken
from the subventricular/subgranular zones of the brain,
or the ependymal canal of the spinal cord, are able to re-
place the cells lost due to the injury process and have re-
sulted in significant improvements [20]. Embryonic stem
cells have the ability to form all required cell types [21],
although their use raises some ethical concerns [22]. Fi-
nally, induced pluripotent stem cells (iPSCs) are advan-
tageous in many ways, including their extensive
reprogramming potential and the possibility of autolo-
gous transplantations [23]. All of these stem cell sources
show exciting promise [24–29], but no single stem cell
source represents an ideal solution. Clearly, therefore,
potential alternative sources should be evaluated to de-
termine whether they represent a significant advantage
over existing options.
Enteric neural stem cells (ENSCs) harvested from the
enteric nervous system (ENS), the intrinsic innervation
of the gastrointestinal (GI) tract, are an attractive option.
ENSCs persist into late adulthood [30, 31] and can be
harvested via routine GI procedures such as endoscopy,
providing the potential for autologous transplantation.
The therapeutic utility of ENSCs for enteric disorders
has been previously explored [32, 33], most recently fol-
lowing transplantation into a murine enteric neuropathy
model, where ENSCs successfully engrafted into the host
tissue and restored gut function [34]. Interestingly, simi-
larities between the central nervous system (CNS) and
ENS has led to several studies evaluating the potential of
ENSCs for CNS disorders [35–37]. Indeed, our lab has
previously utilised an embryonic chick model to examine
the potential of ENSCs for SCI repair [38]. We found
that chick ENSCs expressed markers of cell types rele-
vant for SCI repair, suggesting that ENSCs could pro-
duce the required cell types without genetic
reprogramming, reducing the risk of genomic instability
and associated tumorigenic potential of some other stem
cell sources [39, 40]. We also reported the ability of
ENSCs to survive transplantation into, and form bridg-
ing structures across, the injury zone. However, the em-
bryonic chick model of SCI presents a milder injury
zone than that which develops following adult mamma-
lian SCI. Therefore, for progression to a mammalian SCI
model, we sought to enhance the ability of transplanted
ENSCs to engraft into host tissue. Several laboratories
have shown the ability of the bacterial enzyme chondroi-
tinase ABC (ChABC) to digest the inhibitory CSPGs
within the glial scar, leading to increased endogenous
sprouting and recovery of motor function [41–45]. We
hypothesised that combined treatment of SCI with
ENSC transplantation and ChABC application would
prove more effective than either therapy alone, as has
been shown in previous publications examining the po-
tential of alternative neural stem cell sources [46, 47].
Utilising a rat contusion model of SCI, we demonstrate
for the first time long-term survival of ENSCs within the
spinal cord injury zone, with ENSC grafts evident at 16
weeks post-transplantation. The combined treatments
resulted in a reduction of the cavity area, and retrograde
tracing studies revealed both that ENSC-derived projec-
tions extended through and past the injury zone and
that ENSC transplantation resulted in an increase in the
number of cells projecting caudally through the injury
site. Further, at 16 weeks post-transplantation, the com-
bined treatment resulted in a modest, but significant
functional improvement, and we provide preliminary
safety evidence for a lack of ectopic ENSC migration
from the transplant site over a period of 16 weeks. These
results strongly encourage further investigation into the
use of ENSCs for a range of CNS disorders.
Methods
Animals
SCI was induced in 26 adult female Sprague-Dawley rats
(180–200 g; Harlan Laboratories). Two animals died dur-
ing surgery. Animals were housed together under stand-
ard husbandry conditions with a 12-h light/dark cycle
and access to food and water ad libitum. All experimen-
tal procedures were carried out in accordance with the
UK Animals (Scientific Procedures) Act 1986 under
Home Office Project Licence 70/8032. Following SCI,
animals were randomly assigned to one of four groups
(no treatment; LV (lentivirus)-ChABC injection only,
ENSC transplantation only and ENSC transplantation+
LV-ChABC injection; n = 6 per group) by an
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experimenter whom, following the surgical procedures,
played no further part in the investigation. Animals
within the no treatment group received sham injections
of 0.9% sterile saline, and animals in the single treatment
groups (ENSC transplantation only and ChABC only) re-
ceived additional sham injections of 0.9% saline so that
all groups received the same number of injections. All
analyses were conducted while blinded to the treatment
groups.
Cell isolation, culture and enrichment
The intestines of 3 female neonatal Sprague-Dawley rat
pups (P7) were harvested into Mg2+/Ca2+ free
phosphate-buffered saline (PBS, 0.1 mol L− 1, pH 7.2)
under sterile conditions and the mucosal layer removed
via fine dissection. Intestinal cells from the muscularis
were dissociated and plated (~ 50,000 cells mL− 1), onto
2% fibronectin-coated cell culture dishes. Cells from in-
dividual animals were cultured separately to allow the
quality control of harvests. Two days after tissue harvest,
cells were collected for FACS analysis. Following labeling
with anti-p75 FITC-conjugated primary antibody (Euro-
gentec, Belgium), cells were sorted using a MoFloXDP
cell sorter (Beckman Coulter, UK), 530/40 filter set and
re-plated at the original density. Media was refreshed
every 2–3 days (DMEM F12 (Sigma Aldrich, UK), N2
(Gibco Life Technologies, UK), B27 (Gibco Life Tech-
nologies, UK), primocin (InvivoGen, UK), FGF and EGF
(20 ng mL− 1, Peprotech, UK). Prior to transplantation,
cells were labelled with a self-inactivating (SIN) second-
generation HIV-1-based lentivirus containing mutated
Woodchuck Posttranscriptional Regulatory Element
(WPRE) downstream of enhanced green fluorescent pro-
tein (eGFP) [48] to allow for post-transplantation
visualisation. For transplantation studies, neurospheres
from all animals were collected and pooled, dissociated
into a single-cell suspension, concentrated by centrifuga-
tion (1000 rpm for 5 min) and counted using a haemo-
cytometer with Alcian Blue.
Contusion injury surgery
Contusion injury was induced as previously described
[49]. Briefly, rats received perioperative analgesia (Carpro-
fen 5mg kg− 1) and were anaesthetized (ketamine, 60mg
kg− 1, and medetomidine, 0.25mg kg− 1 administered i.p.),
and a laminectomy performed at T10. Core temperature
was maintained at 37 °C during surgery. A contusion in-
jury of 150 kdyne was induced (Infinite Horizon Impactor,
Precision Systems Instrumentation, Lexington, KY) as pre-
viously described [50]. Measurements of the administered
force and spinal cord displacement were recorded to en-
sure consistency of injuries between animals (Fig. 1a, b).
Following anaesthesia, reversal (atipamezole hydrochlor-
ide, 1 mg kg− 1 administered subcutaneously) animals re-
ceived saline for rehydration (3–4mL, once daily for 3
days), post-operative analgesia (Carprofen 5mg kg− 1, once
daily for 2 days) and antibiotics (Baytril, 5 mg kg− 1, 1 week
course).
Chondroitinase ABC lentiviral vector production
The lentiviral vector containing the Proteus vulgaris
ChABC gene (LV-ChABC) was produced as previously
described [50] and provided as a generous gift from Prof
Joost Verhaagen (Supp. Figure 1). Briefly, the ChABC
gene was modified via the removal of five cryptic n-
glycosylation sites and resynthesized using mammalian-
preferred codons [51]. This was subcloned into a lenti-
viral transfer vector to produce an integrating, self-
Fig. 1 Spinal cord contusion injuries resulted in difficulty traversing the horizontal ladder, which improved over the course of the study. Spinal cord injuries
were induced with an Infinite Horizons impactor. Applied force (a) and spinal cord displacement (b) were consistent between animals. Following injury, the
ability of each rat to traverse the horizontal ladder was assessed at regular time points (c). All rats improved over the course of the study. At the 16week time
point, there was a significant difference between the ENSCs+ChABC and the non-treated group (* indicates significance (p=< 0.05) and between the
ENSCs+ChABC and the ENSC-only group (§ indicates significance (p=<0.005). Data are represented as mean± s.e.m
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inactivating vector, pseudotyped with VSV-G [52]. Viral
particles were concentrated via ultracentrifugation and
titration using a p24 antigen enzyme-linked immuno-
sorbent assay (ELISA) assay to 1 × 109gc (genome cop-
ies) mL− 1, suspended in 0.9% sterile saline solution.
Cell transplantation and LV-ChABC injection
Rats receiving ENSC transplantations/LV-ChABC treat-
ment were anaesthetised and the spinal cord re-exposed
3 days following contusion, as above. All injections were
conducted with a pulled glass needle at a depth of 1 mm.
Individual rats received 1 × 106 cells, divided into 3 injec-
tions: 1 mm rostral to the injury epicentre, into the epi-
centre and 1mm caudal to the epicentre, each of 0.5 μL,
delivered at a rate of 200 nLmin− 1 using an ultra micro-
pump III (World Precision Instruments, Europe). Rats
undergoing LV-ChABC treatments received two intrasp-
inal injections immediately following ENSC transplant-
ation, at the same rostral and caudal sites as the stem
cell transplantations. 0.5 μL of LV-ChABC was delivered
per site at a rate of 200 nLmin− 1. Following all injec-
tions, the needle was left in place for 2 min before re-
traction. Anaesthesia was then reversed and animal
recovery monitored as above. Previous work in our
group has demonstrated no significant effect of control
(GFP) lentiviral constructs on cavity formation, CSPG
pathology, the density of fibres passing through the le-
sion or cell survival compared to sham injections of
0.9% saline [50] and so sham injections in the no treat-
ment group consisted of saline only.
Axon tracing
Retrograde tracing was used to determine whether trans-
planted ENSCs could project axons across the injury site
to reach rostral regions, and to quantify the number of
cells projecting axons caudally through the injury site.
One week prior to study completion, 3 rats (n = 3) from
the non-treated, ENSC transplantation only and ENSC+
ChABC groups were randomly selected. Animals were
anaesthetised and a T12 laminectomy performed (caudal
to the injury site and site of ENSC/ChABC injections,
which were performed at T10). A pulled glass pipette
connected to a Microdrive pump (NanoLiter 2010 In-
jector/Micro 4 Controller, World Precision Instruments)
was lowered into the midline of the spinal cord to an
initial depth of 300 μm, retracted 100 μm and injected at
a rate of 200 nl min− 1 with 2 μl of Fluorogold (FG) (4%,
dissolved in sterile saline, 0.9%). Following injection, the
needle was left in place for 2 min and slowly withdrawn.
Horizontal ladder training
The horizontal ladder test was used as a measure of
locomotor ability/recovery. Prior to surgery, animals
were trained on the task to provide baseline data.
Starting 1 week after surgery, rats were assessed weekly
until study completion by an examiner blinded to the
treatment groups. Rats were placed individually onto a
horizontal ladder 1 m in length, with irregularly placed
rungs. Testing was captured using a Sony DCR-SX30E
Handycam, and the total number of forelimb and hind-
limb footslips was counted for 3 runs.
Sacrifice and tissue harvest
16 weeks post-surgery, rats were deeply anaesthetized
(sodium pentobarbital, Euthatal; 80 mg kg− 1, i.p.) and
perfused through the ascending aorta with 0.9% saline,
followed by ice-cold 4% PFA. The spinal cord was har-
vested at the level of T10 (+/− 5mm), along with the left
lung, right lateral lobe of the liver, right kidney and
spleen. Samples were post-fixed at 4 °C overnight and
stored in PBS. Samples for sectioning were cryopro-
tected overnight at 4 °C in 30% sucrose and transferred
to OCT (Thermo Scientific, USA). Samples were orien-
tated for sagittal sectioning, frozen using − 65 °C isopen-
tane and stored at − 80 °C prior to sectioning. Frozen
OCT-embedded samples were sectioned serially (20 μm)
using a Leica Cryostat at − 22 °C and slides stored at −
20 °C. For all quantitative measurements, every fifth sec-
tion was used.
Immunostaining
Thawed cryosections or cell cultures were post-fixed
with 4% PFA for 8 min and washed in 1XPBS. For im-
munofluorescent staining, samples were blocked with
1% bovine serum albumin (Sigma Aldrich, UK), 0.15%
glycine (Fisher Scientific, UK), 0.1% Triton X-100 (Sigma
Aldrich, UK) and in 1XPBS for 1 h and incubated in pri-
mary antibody (Table 1), diluted in blocking solution,
overnight at 4 °C. Secondary antibody (Table 2) was ap-
plied in blocking solution for 2 h (RT). Coverslips were
mounted using Vectashield (hard set with DAPI, Dako,
UK). Slides were stored at 4 °C. For immunohistochemi-
cal staining, endogenous peroxidase was quenched using
3% H2O2 and 10% methanol in PBS. Non-specific bind-
ing was blocked with 5% normal goat serum in PBS con-
taining 0.1% Triton X-100. Samples were incubated with
Table 1 Primary antibodies
Protein target Host species Concentration Supplier
TuJ1 Mouse 1:500 Covalence
GFP Mouse 1:500 Invitrogen
GFP Rabbit 1:500 Invitrogen
Ki67 Rabbit 1:500 Novocastra
nNOS Rabbit 1:500 Invitrogen
5HT Mouse 1:500 Millipore
Fluorogold Rabbit 1:10,000 Fluorochrome
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primary antibody overnight at RT diluted in blocking so-
lution. Biotinylated secondary antibody diluted in block-
ing solution was applied for 2 h at RT followed by
incubation with avidin-biotin-peroxidase (ABC Elite kit,
Vector Laboratories, Burlingame, CA, USA), and the
colour reaction was developed using 3,3′-diaminobenzi-
dine kit (Vector Laboratories). Sections were air-dried
and coverslipped using Depex (Sigma-Aldrich, St. Louis,
MO, USA).
Eriochrome cyanine staining and analysis
Eriochrome cyanine (EC) staining is commonly used to
detect myelin and was used in this study to demarcate
white and grey matter within spinal cord sections to
allow quantification of cavitation and tissue damage as
previously described [43]. Briefly, slides were thawed at
RT, dehydrated in an ascending series of ethanol solu-
tions and cleared in Histochoice (Sigma Aldrich, UK).
Slides were rehydrated in a reverse series of ethanol so-
lutions and immersed in EC solution (0.16% eriochrome
Cyanine-R, 0.5% sulphuric acid, 0.4% iron chloride, in
ddH2O). Slides were washed in ddH2O and differenti-
ated in 0.5% aqueous ammonium hydroxide. Following a
final ddH2O wash slides were dried at 50 °C and
mounted using DPX (Merck Millipore, Germany).
Treatment groups were randomised prior to analysis.
Sections were imaged using a Zeiss Axioplan microscope
mounted with a Zeiss colour camera and analysed using
Fiji (ImageJ) software [53]. If required, images were
stitched using the MosaicJ plugin [54]. The spinal cord
cavity area was quantified using the ‘magic wand’ tool set
to a tolerance of 6. The injured tissue area + cavity area
was quantified using the ‘magic wand’ tool set to a toler-
ance of 18, and the spinal cord cavity area value sub-
tracted from this number to give the injured tissue area.
In both instances, the area was quantified on every fifth
section through the entire spinal cord. Except where
noted, all analyses were conducted on at least 3 individual
animals (n = 3) from each group, selected at random by an
investigator blinded to the treatment groups.
Cell survival/spread quantification
For all analyses, every fifth section was used. Serial spinal
cord sections of ENSC-transplanted rats were assessed
to determine both survival and spread of transplanted
cells. Treatment groups were randomised prior to ana-
lysis. GFP antibody-labelled sections were imaged using
a Zeiss Axioplan microscope mounted with a Zeiss
colour camera and analysed using FIJI [53]. Images were
stitched using the MosaicJ plugin [54]. For anterior/pos-
terior and dorsal/ventral spread, the section with the
greatest spread was chosen for each rat, and the extent
of spread determined as the farthest GFP+ signal (cells
or projections) in either direction. For left/right spread,
the distance was calculated between the first and last
serial sections in which GFP+ signal could be detected.
The number of GFP+ cells was quantified using FIJI
[53]. Background subtraction was utilised with a rolling
ball of 10 pixels, followed by a median filter set to 1
pixel radius. Cell number was then determined by the
‘find maxima’ function, with a noise tolerance of 544.
Quantification began at the first section to contain a
positive GFP signal and proceeded sagitally until the last
section containing GFP signal. The number of GFP+
cells in each section was pooled to give a total, summed
cell count. The amount of GFP+ pixels was quantified
using the ‘Threshold’ tool, set to a tolerance of between
44 and 255 (measurements limited to a threshold), and
conducted on the same sections as the cell count ana-
lyses. Results were pooled to give a total, summed
intensity.
Quantification of Fluorogold+ cells
The number of Fluorogold+ cells rostral to the lesion
was quantified using unbiased stereology. Every 5th
section was used, with 5 sections examined per ani-
mal. The sections were selected to span the lesion
epicentre. The entire spinal cord area rostral to the
lesion was delineated under a 2× objective, and
counting was performed under a 100× Plan-Apo oil
objective, with a guard zone thickness of 1 μm at the
top and bottom of each section. The optical fraction-
ator probe (Stereo Investigator software version 9,
MBF Biosciences, Williston, VT, USA) was used to
count positive neurons, with a counting frame size of
60 × 60 and a sampling grid size of 268 × 268. Only
cell bodies were counted, determined morphologically
by a clearly defined cell border, the presence of a
Table 2 Secondary antibodies
Target Host species Concentration Supplier Emission wavelength
Rabbit Goat 1:500 Invitrogen 488
Rabbit Goat 1:500 Invitrogen 568
Mouse Goat 1:500 Invitrogen 568
Nuclei (DAPI) N/A 1:1000 Sigma Aldrich 350
Rabbit Goat 1:300 Vector Biolabs Biotinylated
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nucleus (clearly defined nuclear border with no posi-
tive staining inside) and at least one FG+ projection.
The coefficient of error was calculated according to
Gundersen and Jensen [55], with values < 0.1
accepted.
PCR detection of transplanted cell spread
To determine whether ENSCs spread to ‘off-target’ re-
gions following transplantation into the spinal cord,
samples from peripheral organs (right medial lobe of the
liver, spleen, right kidney and left lung) were analysed by
PCR for the presence of Gfp. DNA was extracted from
10 samples (~ 30mg) collected at random from each
organ. Spinal cord cryosections of transplanted animals
confirmed to contain transplanted GFP+ cells by fluores-
cent microscopy were used as a positive control. Sam-
ples were dried at RT, suspended in 25 μL proteinase K
solution (1 μL proteinase K (Sigma Aldrich, UK) and
40 μL DNA extraction lysis buffer (100 mM Tris. Cl, 5
mM EDTA, 0.2%SDS, 200 mM NaCl, pH 8) and heated
to 55 °C for 4 h. Digestion was halted by heating to 85 °C
for 10 min. Cellular debris and other impurities were re-
moved using salt precipitation. 1 μL from each of the 10
samples collected from each organ were pooled and di-
luted in 0.3M NA-Acetate and 70% EtOH. Samples
were incubated on ice for 30 min and centrifuged at 14,
000 g for 30 min at 4 °C. The supernatant was discarded
and the pellet washed in 70% EtOH. Samples were cen-
trifuged at 14,000 g for 15 min at 4 °C, the supernatant
discarded and the pellet re-suspended in 10 μL ddH20.
1 μL of the precipitated DNA solution was used for each
PCR reaction. PCR reactions were conducted in a PCT-
200 Peltier Thermal Cycler (MJ Research Inc. Waltham,
MA, USA) using HotStarTaq DNA Polymerase (Qiagen,
Manchester, UK). Following amplification (Table 3) with
primers designed for rat Gfp and Gapdh (Table 4), PCR
products were analysed on a 2.5% agarose gel alongside
a 25 bp hyperladder (Bioline, London, UK).
qRT-PCR
Total RNA was extracted from p75+ cell cultures using
an RNeasy Mini kit (Qiagen, Hilden, Germany), follow-
ing the manufacturer’s instructions, and the total yield
quantified using a NanoDrop 1000 (Thermo Scientific,
UK). 100 ng RNA was used for first-strand cDNA ampli-
fication using SuperScript VILO cDNA Synthesis Kit
(Life Technologies Ltd., Paisley, UK). Quantitative RT-
PCR was performed using the ABI prism 7500 sequence
detection system (Applied Biosystems) using the Quanti-
tect SYBR Green PCR kit (Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s instructions. Reactions
were performed in triplicate using region-specific
primers for Gapdh, Sox10, TuJ1, Gls1, Nos1, TPh1, Chat,
Gad1 and S100b (Table 4). Gene expression levels were
expressed relative to Gapdh (as a reference housekeep-
ing gene), using a 1/ΔCt calculation.
Statistical analysis
Data are expressed as mean ± s.e.m. GraphPad Prism
software was used for all statistical analyses. Group com-
parisons of EC-demarcated lesion histology and compar-
isons of the number of FG+ cells rostral to the lesion
were analysed using one-way ANOVA, followed by
Tukey’s multiple comparisons post hoc test. Trans-
planted cell spread/survival was analysed using Student’s
t test (two-tailed). p values of < 0.05 were taken as sig-
nificant. Error bars represent standard error.
Results
Combined treatment with ENSCs+ChABC resulted in
significant improvements in the horizontal ladder test
only in week 16
Rats were assessed for their ability to traverse a horizon-
tal ladder. In the early weeks following SCI, all rats
struggled to correctly cross the ladder, with numerous
Table 3 PCR cycling programme
Step Temp °C Time
1 94 3 min
2 94 30 s
3 58 45 s
4; go to step 2, 35 cycles 72 30 s
5 72 2 min
6 4 Hold
Table 4 PCR primers
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‘footslips’. Over the course of the study, all rats im-
proved in this test (Fig. 1c). For the first 15 weeks, there
was no significant difference between any of the groups
in the percentage of correct footsteps. However, at week
16 (the latest time point examined), there was a signifi-
cant difference between the ENSCs+ChABC and no-
treatment group (78.5 ± 2.3 vs 87.47 ± 1.71, p = 0.0206)
and between the ENSCs+ChABC and ENSC-only group
(87.4 ± 1.71 vs 76.8 ± 1.51, p = 0.005).
ENSCs cultured in vitro formed neurospheres containing
dividing cells as well as mature neuronal subtypes
SCI results in extensive loss of a variety of neuronal sub-
types from the injured tissue. To explore the potential of
ENSCs to replace these lost cells, we first characterised
them in vitro. ENSCs were isolated from dissected intes-
tines of WT Sprague Dawley rat pups (P7) via FACS
using antibodies raised against p75 (Fig. 2a shows a typ-
ical FACS profile). After 1 week in culture, p75+ cultures
were harvested and analysed by qRT-PCR. This revealed
expression of the neural crest progenitor marker Sox10,
as well as the pan-neuronal marker Tuj1 and the glial
marker S100b (Fig. 2b). Mature neuronal markers were
also detected at low levels, including Gls1, Nos1, Tph1,
Chat and Gad1 (indicating the production of the neuro-
transmitters glutamate, nitric oxide, serotonin, acetyl-
choline and gamma-aminobutyric acid, respectively).
Brightfield analysis of 1 week-old p75+ cultures revealed
numerous cells with neuronal-like morphology (Fig. 2c),
with neurospheres typically forming after approximately
2 weeks (Fig. 2d). Immunofluorescent investigation re-
vealed several Ki67+ dividing cells (Fig. 2e), indicating
that a subpopulation of cells likely maintained a ‘stem
cell’ state to some degree. However, the majority of cells
were TuJ1+ (Fig. 2f), with some differentiation towards
specific neuronal subtypes including nNOS+ (Fig. 2g)
and 5HT+ (Fig. 2h) neurons. This diversity was typical
of the population of ENSC-derived cells utilised for
transplantation, and henceforth referred to as ENSCs.
Transplanted ENSCs survived transplantation, and LV-
ChABC injection resulted in breakdown of CSPGs
Having determined that ENSCs are capable of differenti-
ation into a variety of neuronal subtypes relevant for
replenishing cells lost through SCI, we next assessed
their ability to survive in the spinal cord injury zone,
with and without the addition of ChABC-containing
lentivirus. 3 days following induction of a spinal cord
contusion, animals assigned to the treatment groups re-
ceived ENSC transplantation and/or LV-ChABC injec-
tion. Spinal cords and other tissues were harvested 16
weeks post-injury.
We first assessed CSPG digestion by ChABC (via de-
tection of Chondroitin-4-sulfate disaccharides (C4S), a
product of ChABC-mediated degradation of CSPGs) and
ENSC survival (via immunostaining with an anti-GFP
antibody). In both the ENSC+ChABC and ChABC-only
groups, C4S+ staining was visible throughout much of
the thoracic spinal cord, appearing concentrated around
the lesion cavity (Fig. 3b, d). The untreated and ENSC-
only groups showed no specific staining (Fig. 3a, c), al-
though background autofluorescence (most likely mac-
rophages) was present in several sections (Fig. 3a).
Numerous GFP+ ENSCs were found within the spinal
cord in both ENSC-only and ENSC+ChABC-treated ani-
mals (Fig. 3c, d). These were mostly located at the ros-
tral edge of the lesion, though substantial spread
towards the caudal limit of the lesion through dorsal or
ventral spared tissue was frequently observed (in some
animals, simultaneous spread both ventral and dorsal to
the lesion was noted). Transplanted ENSCs were almost
invariably found in one or more large clusters and very
rarely found as solitary cells. Both cell bodies and pro-
cesses of transplanted ENSCs appeared to align along
the A/P axis of endogenous tracts. In two animals, trans-
planted ENSCs crossed the injury zone through a
dorsal-ventral ‘bridge’ which bisected the injury zone
(Fig. 3c). In samples treated with both ENSCs and
ChABC, transplanted cells frequently co-localised with
areas of C4S+ staining. Transplanted ENSCs extended
extensive TuJ1+ processes into surrounding host tissue
(Fig. 3e). These projected both towards neighbouring
ENSCs and into the surrounding SC tissue (Fig. 3e, ar-
rowheads). In several instances, single axons projected
rostrally from the transplant site for several millimetres
(Fig. 3f, arrows, and f’, arrowheads).
Transplanted ENSC spread and survival was not affected
by co-application of ChABC
To determine if there was any effect of ChABC on ENSC be-
haviour post-transplantation, serial spinal cord sections of
rats receiving either ENSC-only (Fig. 4a) or ENSCs+ChABC
(Fig. 4b) were stained with an anti-GFP antibody and imaged.
No significant difference in cell spread between the ENSC-
only and ENSCs+ChABC-treated animals was detected,
across either the anterior/posterior (A/P, 2294.15 ± 581.2 μm
vs 2451.05 ± 601.2 μm, p= 0.8573, Fig. 4c), dorsal/ventral (D/
V, 1325 ± 259.4 μm vs 1025 ± 175 μm, p= 0.3747, Fig. 4d) or
left/right (L/R, 1074.55 ± 255.6 μm vs 815.45 ± 173.2 μm, p=
0.4335, Fig. 4e) planes. The numbers of transplanted GFP+
ENSCs detected in the two groups also was not significantly
different (4077.75 ± 598.7 μm vs 2724.5 ± 618.5 μm, p=
0.167, Fig. 4f). Similarly, quantification of the density of
GFP+ pixels revealed no significant difference between rats
receiving ENSC-only and ENSCs+ChABC (542,499.22 ± 180,
444 vs 543,940.69 ± 170,462, p= 0.9956, data not shown). By
all parameters quantified, co-treatment with ChABC had no
effect on transplanted ENSC survival or spread.
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Fig. 2 (See legend on next page.)
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Combined ENSC and ChABC treatment significantly
improved lesion pathology
To assess whether stem cell transplantation and/or
ChABC therapy had any effect on lesion pathology fol-
lowing injury, serial sections were stained with erio-
chrome C (Fig. 5a–d). Quantification of the cavity area
revealed differences between groups (Fig. 5e), and this
was confirmed as significant with ANOVA analysis
(Fig. 5f, F(3, 16) = 5.73, p = 0.0074). There were no sig-
nificant differences in the average total cavity size com-
pared to the untreated group in rats treated with
ChABC alone (16.29 ± 2.563 vs 16.47 ± 5.919 mm2, p = >
0.999) or stem cells alone (11.85 ± 2.968 vs 16.47 ± 5.919
mm2, p = 0.7453). However, cavity area was significantly
reduced in the ENSC+ChABC combination treatment
group compared to non-treated animals (2.72 ± 1.183 vs
16.47 ± 5.919 mm2, p = 0.0309, Fig. 5f).
Lesion cavities were surrounded by injured tissue, notable
in both disrupted organisation and poor eriochrome C stain-
ing. To determine whether the reduced cavity area observed
in the ENSC+ChABC group corresponded to an expanded
area of injured tissue, the lesioned tissue area was also quan-
tified (Fig. 5g). Quantification of the area of injured tissue
yielded results closely mirroring that of the cavity area
(Fig. 5h). ANOVA analysis confirmed a significant difference
between groups (F(3, 16) = 3.622, p = 0.0362). Although there
was a trend for a decrease in lesioned tissue area in the single
treatment groups these were not significantly different for ei-
ther ChABC treatment (27.35 ± 4.127 vs 32.72 ± 6.582mm2,
p = 0.728) or ENSC transplantation (21.83 ± 1.353 vs 32.72 ±
6.582mm2, p = 0.213) compared to the untreated group.
Again, only the combined treatment resulted in a statistically
significant decrease in injured tissue area (17.43 ± 1.195 vs
32.72 ± 6.582mm2, p = 0.0408). Taken together, these results
indicate that the combined treatment results in an increase
in the area of preserved tissue, by decreasing both the injury
cavity and the area of injured tissue.
Transplanted ENSCs project axons through and across the
injury zone and result in a significant increase in the
number of retrograde-labelled neurons crossing the
injury site
To determine whether transplanted ENSCs were capable
of long distance axonal projection bypassing the lesion,
the transplanted rat spinal cords were injected with a
retrograde tracer, fluorogold (FG) caudal to the injury
site (T12), resulting in a substantial number of FG-
labelled neurons rostral of the lesion (Fig. 6a). The
morphology of the stained cells was variable in terms of
both size and number of processes (Fig. 6a’). We also
found multiple instances of FG+ transplanted ENSCs
within the transplant site, indicating that these cells were
sending projections past the injury site to distant caudal
regions (Fig. 6b, arrows indicate co-labelled cells). To
determine whether the observed tissue sparing resulted
in an increased number of tracts bypassing the lesion,
tissue sections were incubated with antibodies raised
against fluorogold and developed with diaminobenzidine
(Fig. 6c) and the number of fluorogold+ neurons rostral
to the lesion was quantified in the untreated, ENSC-only
and ENSC+ChABC groups. No significant difference
was observed between the ENSC+ChABC and ENSC-
only groups (16,421.3 ± 5062 vs 28,046.7 ± 4547, p =
0.5158, Fig. 6d). However, a significant difference was
observed between the ENSC-transplanted and untreated
groups (28,046.7 ± 4547 vs 8057.2 ± 1349, p = 0.0287,
Fig. 6d).
Transplanted ENSCs do not engraft in peripheral organs
or form tumours
Undesired migration and tumorigenesis of transplanted
cells is a potential risk of stem cell-based treatments.
Upon gross dissection and careful examination, no tu-
mours were observed in any of the transplanted animals
after 16 weeks, and mortality within treatment groups was
not found to be different compared to non-transplanted
animals over the course of the study. To test for the pres-
ence of transplanted cells in ‘off target’ locations, we used
PCR to detect the expression of Gfp, indicative of the pres-
ence of transplanted ENSCs in peripheral organ tissue
samples. The lung, liver, kidney, and spleen were assessed
alongside cryosections of transplanted SC tissue, which
had been confirmed to contain GFP-expressing cells and
was therefore used as a positive control. While all samples
revealed expression of Gapdh, only positive control sam-
ples of transplanted SC revealed expression of Gfp (Supp.
Figure 2, arrow), with no Gfp expression detected in any
of the other organs examined.
(See figure on previous page.)
Fig. 2 In vitro cultures of rat-derived ENSCs contain a heterogenous population of dividing progenitor cells and various neuronal subtypes. a
Representative FACS plot showing isolation of p75 FITC-labelled ENSCs. Following FACS, 1 week-old p75+ cultures were analysed by qRT-PCR,
revealing expression of Sox10 (neural crest cell progenitor cell marker), Tuj1 (pan-neuronal marker), Gls1 (glutamine), nNos (neuronal nitric oxide),
Tph1 (serotonin), ChAT (acetylcholine), Gad (GABA) and S100b (glia) (b). c–h In vitro characterisation of ENSCs prior to transplantation. p75-sorted
cell cultures displayed a characteristic neuronal morphology by 1 week in culture, including extension of fine interneuronal processes (c), and
formed dense neurospheres by around 2 weeks (d). A small number of dividing cells were detected by Ki67+ staining (e). However, the vast
majority of cells stained positive for the pan-neuronal marker TuJ1 (f), indicating neuronal differentiation. A subpopulation of cells stained positive
for specific neuronal subtype markers, including nNOS (g) and 5HT (h). Data are represented as mean ± SEM. Scale bar—c, d 200 μm, e 50 μm,
and f, g, h 100 μm
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Discussion
Here, we demonstrate the therapeutic potential of a com-
bined treatment of ENSCs and ChABC for SCI. ENSCs
transplanted into the injured spinal cord of immunocom-
petent rats survived and formed continuous bridges across
the injury zone. The combined treatment resulted in sig-
nificant reductions in the cavity area of injured spinal
cords, and transplanted cells projected axons across the
injury site and increased the number of cells projecting
axons caudally through the injury site. At the latest time
Fig. 3 Immunoflourescent staining reveals the presence of CSPG breakdown products and ENSCs 16weeks post-transplantation. Longitudinal
cryosections of the spinal cords harvested at 16 weeks post-injury were analysed for markers indicative of successful treatment. a–d Representative
images of the spinal cords in the untreated (a), ChABC-treated (b), ENSC-treated (c) and ENSC+ChABC-treated (d) groups. Asterisks indicate lesion
cavity. Chondroitin-4-sulfate disaccharides (C4S), a breakdown product of CSPGs, were detected by immunoflourescent staining following treatment
with ChABC (b, d). In rats receiving ENSC transplantation, ENSCs could be seen within the spinal cord injury zone (c, d). ENSCs extended substantial
processes from the transplantation site (e, arrowheads), often for several millimetres (f, arrows indicate maximum detected length of a single GFP+
fibre). The boxed area in f is shown at a higher magnification in (f’). Arrowheads indicate the path of the GFP+ fibre. Scale bar—d 1mm, e 200 μm,
and f 500 μm
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Fig. 4 Application of ChABC has no effect on ENSC spread/behaviour. a, b Representative images of transplanted ENSCs within the ENSC-treated
(a) and ENSC+ChABC-treated (b) spinal cords. At the time of tissue harvest (16 weeks post-injury), numerous GFP+ cells were found within sagittal
spinal cord sections of both the ENSC-only group (a) and the ENSC+ChABC groups (b). c–f Serial spinal cord sections spanning the extent of
GFP+ cell detection were analysed for cell spread across the anterior/posterior (c), dorsal/ventral (d) and left/right planes (e), as well as for cell
survival (f). No significant differences were detected in any parameter between animals treated with ENSCs+ChABC or with ENSC-only. Data are
represented as mean ± s.e.m. Scale bars—a, b 500 μm
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Fig. 5 (See legend on next page.)
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point examined, the combined treatment of ENSCs+
ChABC led to a small but significant increase in the ability
of injured rats to traverse the horizontal ladder. These
data suggest that ENSCs, particularly in combination with
other therapeutic interventions, may serve as a viable sub-
stitute for other, less widely available stem cell sources.
The horizontal ladder test has been utilised previously
as an assessment of motor function recovery following
SCI [43]. In the current study, we found no significant
difference between the groups until the final week
assessed, week 16, at which point the combined treat-
ment group performed significantly better than the no
(See figure on previous page.)
Fig. 5 Combined treatment of SCI with ENSCs and ChABC resulted in significant reductions in tissue pathology, as assessed by eriochrome
cyanine staining. a–d Representative sagittal sections of the spinal cords from each treatment group harvested from animals sacrificed 16 weeks
post-injury and stained for eriochrome C. e–h Summary data of cavity area (e, f) or injured tissue area (g, h) analysis. ENSC transplantation or
ChABC application applied as single treatments did not significantly affect the cavity size or the area of injured tissue. However, in the combined
treatment group, there was a significant decrease in both cavity area and the area of injured tissue compared to the non-treated group. Data are
represented as mean ± s.e.m. *Indicates significance (p ≤ 0.05). Scale bar—a 500 μm
Fig. 6 Transplanted ENSCs project axons through and past the injury site to reach caudal spinal cord regions. Fluorogold, a retrograde tracer, was
injected caudal to the injury site (T12) at 15 weeks post-injury (1 week prior to sacrifice of animals at week 16). a Representative tile scan of the
injury epicentre and rostral spinal cord of a rat treated with ENSCs only. Asterisk indicates injury cavity. a’ High magnification of boxed area in (a),
indicating FG-labelled neurons (arrows). Frequent instances of transplanted, GFP+ ENSCs (b) co-labelled with FG (b’) were found (b” shows
merged image of b and b’). Following incubation with a fluorogold antibody and development with diaminobenzidine (c), the number of FG+
cells rostral to the lesion was quantified using unbiased stereology (d). Data are represented as mean ± s.e.m. *Indicates significance (p≤ 0.05).
Scale bars: a 500 μm, b 50 μm, and c 25 μm
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treatment and ENSC-only treatment. These results are
in line with previous publications examining the com-
binatorial application of neural stem cells and ChABC
[46, 47], which have reported significant benefits in a
wide variety of behavioural tests, including a panel of
gait analyses and Basso, Beattie and Bresnahan (BBB)
analysis. The modest improvements observed in the
current study are promising and should be further evalu-
ated with a larger sample size and more comprehensive
variety of behavioural tests to ascertain the true extent
of functional recovery.
Simultaneous treatment with ChABC and ENSC trans-
plantation resulted in significant reductions in both af-
fected tissue area and cavity area, both of which are often
used as a neuroprotective marker in cell transplant studies
[50, 56–58]. ChABC+ENSC treatment caused a decrease
in cavity area of approximately 83.5%. Comparatively,
Führmann et al., who treated injured spinal cords with
ChABC immediately following injury and transplanted
cells 1 week later, noted reductions in cavity volume of
around 50% following application of induced pluripotent
stem cell (iPSC)-derived neuroepithelial cells, either alone
or in combination with ChABC [59]. Nori et al., who ad-
ministered ChABC 6 weeks following injury and trans-
planted cells 1 week later, detected no such improvement
in tissue preservation (although they noted impressive
locomotor recovery) following combined treatment of hu-
man oligodendrogenic neural progenitor cells with
ChABC [60]. Combined, these findings suggest that for
stem cell-based treatments, early interventions in the
acute injury phase may be required to limit and/or reverse
cavity formation. The effect of timing is also likely a key
factor in mediating neuroprotective effects of ChABC-
based interventions [61]. Previous publications have
shown that ChABC treatment can have beneficial immu-
nomodulatory effects when administered immediately
post-injury via lentiviral delivery (Bartus et al., 2014; James
et al., 2015) or when given as high-dose bolus injections of
enzyme either prior to or within 1 h post-injury [62]. In
contrast to previous studies, we observed no significant
difference in the cavity area between the ChABC-only and
untreated groups. This is likely due to differences in tim-
ing, since we observed a similar pattern of widespread
CSPG digestion to that of Bartus et al. [50], but LV-
ChABC was administered with a 3-day delay. Importantly,
Bartus et al. showed that by 3 days post-injury LV-ChABC
treatment had significantly altered the immune cell
phenotype. Thus, the 3-day delay in treatment likely un-
derlies the lack of neuroprotection due to a lack of early
immunomodulation. Notably, a publication by Sarveazad
et al. noted the beneficial effects of ChABC on cavity size
(alone or in combination with human adipose-derived
stem cells) when transplanted 1 week post-injury [63].
This treatment involved direct injection of the enzyme
rather than a viral construct, making a direct comparison
difficult. However, the current study used injections of
ChABC lentivirus at a concentration of 1 × 109gc—a
slightly lower titre compared to our previous publication
[64]. Sarveazad et al. used a particularly high dose of
ChABC (10 μL of 100 U/mL) compared with other publi-
cations [46, 47, 65]. Previous publications have demon-
strated that the concentration of ChABC administered to
the injured spinal cord is vital for adequate digestion of
CSPGs [65], and this discrepancy may explain the vari-
ation in results. Interestingly, while acute administration
of LV-ChABC may be crucial for mediating immunomod-
ulatory and neuroprotective effects when delivered alone,
in the present study, we found that in combination with
ENSCs, LV-ChABC enables significantly reduced injury
pathology over ENSCs alone.
As co-application of ChABC with ENSC transplant-
ation enhanced cavity reduction compared to ENSCs
alone, it may have been expected that ChABC was fulfill-
ing a supporting role towards transplanted ENSCs. Sur-
prisingly however, we found no significant difference in
transplanted cell characteristics between the ENSC-only
and ENSCs+ChABC groups, as assessed by transplanted
cell spread analysis, GFP+ transplanted cell counting
and GFP+ immunostaining threshold analysis of trans-
planted tissue. These results are in line with a previous
publication which found no difference in survival of cells
when transplanted with or without ChABC-loaded
microtubes [66]. The lack of a difference in any of the
parameters examined in the current study suggests that
the two treatments have independent, supportive effects
on endogenous tissue. ChABC has been shown to en-
hance both endogenous axon regeneration and preserva-
tion of vulnerable neuronal tracts after SCI ([43],
reviewed in [67]), and additional studies have demon-
strated that transplanted stem cells can secrete neuro-
trophic factors to support the survival of host tissue [68,
69]. ENSCs transplanted into the injured SC in the
current study may exert a similar paracrine-driven effect
on endogenous tissue. Although to the best of our
knowledge, it is currently unknown what, if any, factors
may be secreted by ENSCs, in their paper utilising trans-
plantation of ENSCs into the injured mammalian brain,
Belkind-Gerson et al. noted that the transplanted cells
appeared to stimulate endogenous neurogenesis, possibly
by secretion of stimulatory factors [35]. In addition, nu-
merous studies have demonstrated the potential of
transplanted cells, such as olfactory ensheathing glia
(OEGs), to form bridges for endogenous axons to follow
across the injury site [70, 71]. It is possible that ENSCs
fulfilled a similar role in the current study, with ChABC
supporting the sprouting or survival of endogenous
axons across these bridges. Indeed, a previous publica-
tion by Carwardine et al. noted increased endogenous
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sprouting in a cervical dorsal crush spinal cord lesion
following transplantation of ChABC-expressing olfactory
ensheathing cells (OECs) [72]. In this study, the authors
noted significantly more endogenous sprouting in the
animals transplanted with OECs+ChABC, compared to
OECs alone, again indicating a synergistic effect of the
two treatments. In the current study, we found frequent
instances of transplanted ENSCs closely associated with
TuJ1+ endogenous tracts, likely helping to preserve sur-
viving and/or sprouting tracts.
Transplanted ENSCs often extended in a continuous
chain across the injury site, potentially providing a
bridge for regenerating endogenous axons to bypass the
lesion. Maximum spread or outgrowth of transplanted
ENSCs reached 4.2 mm along the A/P axis. Using a simi-
lar methodology, we have previously shown a spread of
approximately 5.5 mm2 following transplantation of
ENSCs into the colon, arguably their ‘natural’ environ-
ment [34]. The similar level of spread suggests that
ENSCs are able to adapt to the CNS environment. While
the current study marks the first time ENSCs have been
transplanted into the mammalian spinal cord following
injury, publications describing the spread of other stem
cells post-transplant are numerous and appear to show
high variation. For example, Lepore and Fisher noted
cell migration of up to 15mm following transplantation
of embryonic neuronal and glial-restricted progenitors
embedded in a collagen matrix [73]. However, the au-
thors noted that the degree of spread was highly incon-
sistent between animals. Other publications have instead
measured the distance of cell projections, often using
co-application of additional factors to boost outgrowth.
Wictorin and Bjorklund observed fibre outgrowth up to
10mm from the transplant site [74]. Lu et al. observed
extension of axons up to ~ 20mm [75] following the
combinatorial application of fibrin scaffolds supple-
mented with a cocktail of growth factors including
BDNF and GDNF. Future work will aim to optimise
conditions to promote the outgrowth of transplanted
ENSC processes.
A major obstacle for promoting motor/sensory recov-
ery following SCI is the difficulty in encouraging axonal
sprouting of endogenous or transplanted neurons
(reviewed in [76]). This has led to several groups investi-
gating combined therapies, such as co-application of
stem cells with scaffolds, in an attempt to encourage
stem cell-derived axon growth [77]. As such, the fre-
quent instances of FG+ ENSCs found around the injury
zone in both the ENSC-only and ENSC+ChABC groups
in the current study are very encouraging and indicate
that a subpopulation of transplanted cells project axons
through/past the injury site to reach caudal host tissue.
FG is a retrograde tracer and is not known to diffuse
from labelled cells. Therefore, it is incredibly unlikely
that the FG could have been passed from a labelled, en-
dogenous cell to a transplanted GFP+ cell. Following the
quantification of the total number of FG+ cells rostral to
the lesion, we found significantly higher numbers of
FG+ neurons in the ENSC-transplanted group compared
to the non-treated group. Similar increases in the num-
ber of cells crossing the lesion have been noted following
transplantation of cells from established stem cell
sources. Zhou et al. observed an increase in the number
of FG+ axons crossing the injury site following com-
bined treatment with bone marrow-derived mesenchy-
mal stem cells and propofol (an anaesthetic thought to
be neuroprotective, possibly via its antioxidant and
apoptosis-inhibiting properties) [78]. Other studies uti-
lising neural crest-derived cells such as Schwann cell or
OEG cell grafts have also resulted in increased FG+ neu-
rons crossing the injury site [79]. This further demon-
strates that, at least for the purposes of neuroprotection,
ENSCs can serve as a viable substitute for other, more
difficult to access stem cell sources.
As well as the effect of transplanted cells upon en-
dogenous tissue, the fate of the transplanted cells them-
selves is of key importance. Previous reports of cell-
based therapies have documented such extensive glial
differentiation following transplantation into the spinal
cord as to suggest that astrocytic differentiation of trans-
planted progenitor cells may be the default pathway [80,
81]. In contrast, our in vitro qRT-PCR data revealed ex-
pression of a panel of mature neuronal markers, includ-
ing Gls1, Nos1, Tph1, Chat and Gad1, similar to
previous work by our lab on chick-derived ENSCs [38].
We used immunofluorescence to confirm the presence
of 5HT+ and nNOS+ neurons. Thus, transplanted
ENSCs have the potential to replace neurons lost
through the injury process, and indeed, we found fre-
quent TuJ1+ ENSCs post-transplantation. It must be
noted that we also detected expression of the glial
marker S100b in our in vitro studies. Further work will
determine the specific neuronal subtypes ENSCs differ-
entiate into post-transplantation, and whether they con-
tribute glia to the injury zone.
Tumorigenesis following stem cell transplantation is a
recognised concern of stem cell applications [39, 40, 82–
84]. In a recent publication by Hirota et al., teratomas
were observed in nearly one third of mice transplanted
with iPSC-derived cells 9–10 weeks post-transplantation
[85], highlighting the need for thorough safety assess-
ments before progression to clinical trials. Encour-
agingly, we found no evidence of tumour formation in
rats at 16 weeks post-transplant. We also used PCR ana-
lysis of peripheral organs to detect the spread of GFP-
labelled transplanted cells, but only found GFP expres-
sion in transplanted SC tissue, in line with long-term
safety results previously published by our group [86].
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The results described in the current study therefore pro-
vide initial evidence of the safety of ENSC transplant-
ation into the spinal cord, but further long-term analysis
of ENSC proliferation post-transplantation, and genetic
sequencing to confirm that genetic instability does not
occur in ENSCs (as it can in iPSCs [87]) will be
required.
Notably, it is likely that any harvest and expansion of
ENSCs will take longer than 3 days, and so, transplant-
ation at 3 days post-injury, as in the current manuscript,
will likely be difficult to replicate in the clinical setting.
Future experiments will aim to determine the earliest
time point at which patient-derived ENSCs could be ex-
panded sufficiently for transplantation. Similar to previ-
ous reports [35, 88, 89], in our study, ENSCs were
expanded in vitro for 2 weeks prior to transplantation.
Encouragingly, work by Didangelos et al. demonstrated
that ChABC applied 1 h post-injury and hence every 48
h (up to 7 days) was able to promote an anti-
inflammatory environment within the injury zone [62].
A comprehensive evaluation of the potential of therapies
such as ChABC application to prime the injury environ-
ment while autologous stem cells are expanded in vitro
will be vital.
Conclusions
We show that ENSCs isolated from the ENS of the GI
tract have therapeutic potential for the treatment of SCI,
in terms of reducing cavity/injured tissue area and pro-
jecting axons rostrally through the injury zone to reach
spared tissue caudal to the lesion. These effects were en-
hanced when combined with ChABC and led to a mod-
est but significant functional improvement as assessed
by the horizontal ladder test. Transplanted ENSCs sur-
vived up to the latest time point examined (16 weeks),
and preliminary evidence suggests that ENSCs did not
migrate to undesired areas. These results strongly en-
courage further exploration of the use of ENSCs for both
SCI and a range of CNS disorders.
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